Nicola Redfern | Director
NJ Redfern Ltd.

Nicola Redfern, Director, NJ Redfern Ltd.

Nicola set up NJ Redfern Ltd over 2 years ago in 2022 to enable her to consult, coach and collaborate with other organisations in the area of early launch planning (strategic and operational) and market access, ensuring people living with life threatening and/or life limiting conditions can access new innovations rapidly. She has since engaged with over 18 different organisations both within the pharma/biotech world but also with other companies, the NHS, and charitable organisations on a diverse array of projects, and is passionate about early engagement across all different stakeholders.

Following 5 years’ experience working in the gene therapy arena at bluebird bio, with a focus on reimbursement and commercialisation, she became knowledgeable and passionate about the ATMP arena and has remained focussed on during her consultancy and advisory work– including supporting 2 further gene therapy companies in their launch planning in the UK, and working with the ATTC network on their event and subsequent recommendations on what needs to still evolve in the UK to ensure access to the future innovations coming through . Nicola was previously an active member of the ABPI - chairing the ATMP working group during 2021, a member of their Value and Access group and supporting various government affairs/communications initiatives. She has worked closely in the last 7 years with the Cell and Gene therapy catapult in the UK, sits on the advisory board for company ATMPS, has given talks at various ATMP congresses, been interviewed by Lumanity and Haemnet, and is a member of the ethics subgroup of the International Society of Cell and Gene therapy and a member of ATMP engage in the UK. 

With a consistent focus over recent decades on rare disease & oncology/ haematology, she is also now involved supporting 2 new organisations in their launch planning in the rare disease arena. 

Nicola is committed to and motivated by patients having a choice and being able to access transformative treatment options quickly once science and innovation reaches a point to positively impact the lives of people living with significant health challenges. Having worked at Martin House hospice in Yorkshire, sat on the board of trustees at Naomi House and Jacks Place - a Hospice for children and young adults near Winchester, UK – and through working alongside multiple patient organisations over her career, she has a strong empathy and understanding of life limiting conditions and their impact on the individual, their families and society as a whole. 

She has consistently demonstrated strong leadership capabilities - with a passion for creating and shaping new diverse teams - embedding a positive culture and focus on what is valuable to those that might benefit, whilst helping individuals develop, then leading them through defining their strategic focus and driving the initiatives through to completion.

Appearances:



Day 2: 19th March 2025 @ 09:45

Keynote Panel Discussion: The Affordability of ATMPs: Striking the balance between commercial interests and patient uptake

last published: 05/Nov/24 17:25 GMT

back to speakers


Get Involved with Advanced Therapies Congress

 

To sponsor or exhibit

Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032

 

To speak

Chris Shanks
Chris.Shanks@terrapinn.com
+44 207 092 1150